HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or...
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the...
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or...
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE...
NGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a...
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.